Genmab shares double on cancer drug trial wins

· Health · Denmark

Genmab's shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops, CNBC reported. The Danish biotech's high-stakes cancer bet paid off, drawing investor attention to its pipeline and strategy of retaining more rights to its drugs rather than licensing them out. The rally shows how positive trial data can rapidly revalue a mid-sized biotech company.

Why it matters：The rally illustrates how clinical success can transform a biotech's fortunes and encourages firms to retain drug rights rather than license them, shaping the industry's dealmaking.

Key points

  • Genmab shares doubled in three months.
  • The gains followed a string of cancer drug trial wins.
  • The company is pushing to own more of the medicines it develops.

Sources (original reporting)

More stories from this day